Allianz Asset Management
KERX

Allianz Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Allianz Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-330,892
Closed -$4.68M – 2415
2014
Q4 		$4.68M Sell
330,892
-1,126,295
-77% -$17.5M 0.01% 1242
2014
Q3 		$20M Sell
1,457,187
-33,833
-2% -$518K 0.02% 640
2014
Q2 		$22.9M Sell
1,491,020
-32,046
-2% -$454K 0.03% 527
2014
Q1 		$26M Buy
1,523,066
+37,128
+2% +$560K 0.03% 481
2013
Q4 		$19.2M Buy
1,485,938
+1,302,058
+708% +$15.5M 0.02% 552
2013
Q3 		$1.86M Buy
+183,880
New +$1.64M ﹤0.01% 1213

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Allianz Asset Management's KERX Position: Q1 2015 in Review

Allianz Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 330,892 shares — an estimated $4.68M sold.

Allianz Asset Management first reported a position in KERX in Q3 2013 and held it in 6 quarters. The position peaked at $26M in Q1 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • Allianz Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Allianz Asset Management sold 330,892 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $4.68M.
  • Allianz Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 6 quarters.
  • Allianz Asset Management's Keryx Biopharmaceuticals Inc position peaked at $26M in Q1 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on Allianz Asset Management's 13F filing for Q1 2015, filed 15 May 2015.